AngioDynamics Files 8-K on Financials and Operations

Ticker: ANGO · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1275187

Angiodynamics Inc 8-K Filing Summary
FieldDetail
CompanyAngiodynamics Inc (ANGO)
Form Type8-K
Filed DateOct 3, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, sec-filing

Related Tickers: ANGI

TL;DR

AngioDynamics dropped an 8-K on Oct 3rd covering financials and operations - check it out!

AI Summary

On October 3, 2024, AngioDynamics, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and financial condition, as well as disclosures related to Regulation FD and financial statements. The report was filed from Latham, New York.

Why It Matters

This 8-K filing provides crucial updates on AngioDynamics' financial health and operational status, which are important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a standard 8-K filing reporting on financial condition and operations, which is routine for publicly traded companies.

Key Players & Entities

  • AngioDynamics, Inc. (company) — Registrant
  • October 3, 2024 (date) — Filing date and earliest event reported
  • Latham, New York (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for AngioDynamics, Inc.?

The primary purpose is to report on AngioDynamics, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.

When was this 8-K report filed with the SEC?

This 8-K report was filed on October 3, 2024.

Where are AngioDynamics, Inc.'s principal executive offices located?

AngioDynamics, Inc.'s principal executive offices are located at 14 Plaza Drive, Latham, New York.

What is the Commission File Number for AngioDynamics, Inc.?

The Commission File Number for AngioDynamics, Inc. is 000-50761.

What standard industrial classification code is associated with AngioDynamics, Inc.?

AngioDynamics, Inc. is associated with the standard industrial classification code 3841, which is for Surgical & Medical Instruments & Apparatus.

Filing Stats: 962 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-10-03 07:30:24

Key Financial Figures

  • $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

02 – Results of Operations and Financial Condition

Item 2.02 – Results of Operations and Financial Condition. On October 3, 2024, AngioDynamics, Inc. ("AngioDynamics") issued a press release announcing financial results for the fiscal first quarter ended August 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1. The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. Presentation slides discussing AngioDynamics and its fiscal first quarter ended August 31, 2024 are furnished herewith as Exhibit 99.2. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of produ

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated October 3, 2024. 99.2 Presentation, dated October 3, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: October 3, 2024 By: /s/ Stephen A. Trowbridge Name: Stephen A. Trowbridge Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.